EasyManua.ls Logo

InMode EVOLVE X - Page 34

Default Icon
58 pages
Print Icon
To Next Page IconTo Next Page
To Next Page IconTo Next Page
To Previous Page IconTo Previous Page
To Previous Page IconTo Previous Page
Loading...
Section 6: Transform Treatment Information
29
Contraindications in the use of the EvolveX System in EMS-TENS mode
include:
Active electrical implant/device in any region of the body, including
pacemaker or internal defibrillator.
Permanent implant in the treated area such as metal plates, screws or
silicon, metal piercing or other.
Current or history of skin cancer, or current condition of any other type
of cancer, or pre-malignant moles.
Severe concurrent conditions, such as cardiac disorders, sensory
disturbances, epilepsy, uncontrolled hypertension, and liver or kidney
diseases.
Pregnancy and nursing.
Impaired immune system due to immunosuppressive diseases such as
AIDS and HIV or use of immunosuppressive medications.
Patients with history of diseases stimulated by heat, such as recurrent
Herpes Simplex in the treatment area, may be treated only following a
prophylactic regimen.
Patients with history of diseases stimulated by heat, such as recurrent
Herpes Simplex in the treatment area, may be treated only following a
prophylactic regimen.
Poorly controlled endocrine disorders, such as Diabetes, or thyroid
dysfunction and hormonal virilization.
Any active condition in the treatment area, such as sores, Psoriasis,
eczema, and rash, open lacerations, abrasions or lesions, infection in
the area to be treated.
History of skin disorders, keloids, abnormal wound healing, as well as
very dry and fragile skin.
History of bleeding coagulopathies or use of anticoagulants except for
low-dose aspirin.
Impaired immune system due to immunosuppressive diseases such as
AIDS and HIV or use of immunosuppressive medications.
Any surgical procedure in the treatment area within the last 12 months
or before complete healing.
(Accutane) within last 6 months.
Having received treatment with light, laser, RF, or other devices in the
treated area within 2-3 weeks for non-ablative procedures, and 6-12

Table of Contents

Related product manuals